Prelude Corporation (PreludeDx)

Prelude Corporation, operating as PreludeDx, is a privately held company specializing in precision diagnostics for early-stage breast cancer. Headquartered in Laguna Hills, California, the company's mission is to deliver innovative technologies that enhance patient outcomes and reduce healthcare costs by making precision diagnostic testing accessible and providing physicians with critical information for treatment decisions.

PreludeDx's primary product is DCISionRT®, a validated genomic test designed for women diagnosed with ductal carcinoma in situ (DCIS). This test provides individualized recurrence risk assessment and predicts the benefit of radiation therapy. The company also offers AidaBreast, a test for invasive breast cancer.

In June 2026, PreludeDx announced a significant milestone for DCISionRT®, with over 3,000 breast cancer physicians having ordered the test for more than 45,000 patients. Currently, one in three DCIS patients undergoing breast-conserving surgery in the United States utilize DCISionRT to inform shared decision-making. Key leadership includes Dan Forche as President & CEO, Andrew Wade as CFO, and Dr. Pat Whitworth as Chief Medical Officer.